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Abstract
Background: Trials in adults suggested that, in ulcerative colitis [UC], once-daily [OD] dosing of 
5-ASA [5-amino salicylic acid] may be as or more effective than twice-daily [BD] dosing. In this 
induction of remission, investigator-blinded, randomised controlled-trial, we aimed to compare 
effectiveness and safety of once- versus twice-daily mesalazine in paediatric UC.
Methods: Children, aged 4–18 years with a PUCAI [Paediatric Ulcerative Colitis Activity Index] of 10–55 
points at inclusion, were randomised in blocks of six with blinded allocation to OD or BD mesalazine, 
using a weight-based dosing table. The primary outcome was mean PUCAI score at Week 6.
Results: A total of 83/86 randomised children were eligible and analysed: 43 in the OD group and 
40 in the BD group (mean age 14 ± 2.7 years, 43 [52%] males, 51 [62%] extensive colitis). The groups 
did not differ with regard to disease activity or any other parameter at baseline. There was no 
difference in median PUCAI score between the OD group and BD group at Week 6: 15 ( interquartile 
range [IQR] 5–40) versus 10 [0–40]; p = 0.48]. Response was seen in 25 [60%] OD versus 25 [63%] 
BD dosing [p = 0.78]. Proportion of children in remission [PUCAI < 10] at Week 6 was 13 [30%] OD 
versus 16 [40%] BD; p = 0.35]. Most adverse events were related to disease aggravation; the rates 
of serious adverse events were similar [p > 0.2].
Conclusions: In this first randomised controlled trial in children, no differences were found 
between OD and BD dosing for any clinical outcome. Remission was achieved in 35% of children 
treated with mesalazine for active UC.
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1. Introduction
Several randomised controlled trials performed in children and adults 
have affirmed the efficacy of 5-aminosalicylic acid [5-ASA] and sul-
phasalazine in the treatment of mild to moderate flares of ulcerative 
colitis [UC], as well as in maintaining remission.1–6 Initially, common 
practice was to prescribe 5-ASA in three divided doses. Since transit 
time of the colon is much slower than the small bowel, and since the 
active ingredient acts locally on the colon, less frequent dosing of the 
regular formulation may provide sufficient colonic coverage. Indeed, 
two studies among adults with UC suggested that once-daily dosing 
of mesalazine may be as or more effective than twice-daily dosing 
and superior to placebo.7–10 Similarly, the non-inferiority hypothesis 
was met for once daily dosing of mesalazinein a 1-year maintenance 
controlled trial.11 Slow release once-daily mesalazine with Multi 
Matrix System [MMX] technology was also shown to be effective in 
induction and maintenance of remission in adult UC.12,13
To date, most controlled trials regarding 5-ASA have been 
conducted among adult patients, and efficacy in children has been 
extrapolated from these data. However, the prevalence of extensive 
colitis proximal to the splenic flexure is doubled in paediatric-onset 
UC14,15 compared with adults,16 and extensive disease is consistently 
associated with more severe phenotype.17–21 It has been found that 
less than 50% of children with inflammatory bowel diseases [IBD] 
are adherent to treatment.22 Therefore, the advantage of once-daily 
dosing of 5-ASA over twice-daily may be greater in children.
The primary aim of this trial was to evaluate effectiveness of once-
daily dosing of mesalazine compared with twice-daily in children 
with active UC. We hypothesised the once-daily dosing is superior 
to twice daily, mainly given the increased adherence. As secondary 
aims we also evaluated adherence to treatment and adverse events. 
This manuscript is reported according to the CONSORT statement.
2. Materials and Methods
2.1. Design
This was a multicentre, investigator-initiated, randomised con-
trolled, investigator-blinded, induction of remission trial of once- 
versus twice-daily dosing of mesalazine for active UC in paediatric 
patients with 1:1 allocation ratio.
2.2. Participants
Children, 4–18 years of age with a body weight ≥ 15 kg, a con-
firmed diagnosis of UC by accepted criteria,23 and in mild to mod-
erate disease activity according to the Paediatric UC Activity Index 
[PUCAI; score 10–55 points] were eligible for enrolment regard-
less of disease duration. Exclusion criteria were proctitis only, IBD 
unclassified, current systemic infection, presence of stool patho-
gens at screening [culture, parasites, and Clostridium difficile], and 
significant concurrent illness [eg, renal and hepatic failure or pan-
creatitis]. Rectal therapy was allowed if stable during the 14 days 
preceding screening and without any change until the completion 
of the trial. Immunomodulators and biologics were allowed if 
dose was stable for at least 90 days preceding screening and until 
the completion of the trial. Other medications (eg, steroids, non-
steroidal anti-inflammatories] NSAIDs and anti-diarrhoeal) were 
not allowed. We enrolled children naïve to 5-ASA or those who 
were treated with a low dose < 50 mg/kg/day. A sensitivity analy-
sis was planned a priori excluding those treated with low 5-ASA 
dosing, but since there were less than five such children this was 
not performed.
Participants were enrolled from 13 secondary and tertiary hospi-
tals and medical centres, 12 in Israel and one in Finland.
2.3. Interventions
Children were randomised into two arms: once [OD]- and twice 
[BD]-daily mesalazine granules in 1- g sachets using a weight-based 
dosing table [Table 1]. Doses was based on the standard paediatric 
5-ASA dosing [75 mg/kg/day24] rounded to a multiples of 500 mg, 
with a maximum of 3 g daily, as used previously in the adult trials of 
once-daily mesalazine.
Seven visits were scheduled until Week 9 when safety was assessed; 
four in-house visits [screening at Weeks -2 to -1, Week 0, Week 3, and 
Week 6 which was the primary outcome visit], and three telephone 
visits [Week 1, Week 2, and Week 9 to assess safety and PUCAI score].
2.4. Outcomes
The primary outcome was the PUCAI score between the two arms 
at Week 6. The PUCAI is a valid and reliable disease activity score, 
recently approved by the European Medicines Agency to be used 
as the primary outcome when endoscopic evaluations are not per-
formed, as in this trial, following the guidelines of the paediatric 
committee of ECCO [P-ECCO].25 Cutoff values that correspond 
to remission [< 10 points], mild [10–34 points], moderate [35–60 
points], and severe [> 60 points] disease activity as well as response 
[change of at least 20 points] have been established and validated.15,26
Complete remission was defined as remission [PUCAI < 10 points] 
and a change of at least 10 points from baseline. Response was defined 
as improvement of at least 20 points but still active disease [PUCAI 
≥ 10]. Treatment failure was defined as a lack of improvement of at 
least 10 points from baseline to Week 3, or requirement of corticos-
teroids at any time. Patients with treatment failure have been treated 
at the discretion of the responsible physician, and their latest observa-
tions were carried forward for the intention to treat [ITT] analysis.
Secondary outcomes included remission rate [PUCAI < 10 
points] and treatment success [ie, ∆PUCAI of 20 points or remission] 
at Weeks 3 and 6, adverse events [including urinalysis exploring for 
proteinuria, haematuria, leukocytes, and glycosuria], faecal calpro-
tectin [FC], C-reactive protein [CRP], erythrocyte sedimentation rate 
[ESR], haemoglobin and albumin at Week 6, quality of life at Week 6 
measured by the validated IMPACT questionnaire, and compliance 
with treatment between the groups judged by self-reporting and the 
Medication Adherence Rating Scale [MARS].11
2.5. Randomisation and concealment of allocation
Patients were randomised in blocks of six stratified by weight groups 
[15–< 30 kg, 30–40 kg, > 40 kg], at a 1:1 ratio. Randomisation code 
Table 1. Dosing schedule.
Weight range Group Morning  
mesalazine  
dosing
Evening  
mesalazine  
dosing
15–< 20 kg Once daily 1000 mg
Twice daily 500 mg 500 mg
20–< 30 kg Once daily 1500 mg -
Twice daily 1000 mg 500 mg
30–< 40 kg Once daily 2000 mg -
Twice daily 1000 mg 1000 mg
≥ 40 kg Once daily 3000 mg -
Twice daily 1500 mg 1500 mg
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was prepared and held by the pharmacy of the coordinating site. 
Each patient allocation appeared in a sealed, opaque, numbered, 
and pre-packed box containing the study medications, opened after 
obtaining consent and age-appropriate assent. The box contained all 
required medications and instructions whether to take the prescribed 
total daily dose in two divided doses or once daily. A physician not 
involved in the study provided further instructions.
2.6. Blinding
This was an investigator-blinded and analysis-blinded study. Blinding 
of the patients was not desired as adherence to therapy was considered 
an important factor in determining the optimal number of daily doses. 
The physicians who completed the PUCAI were blinded to the treat-
ment allocation. In addition, the allocation code was revealed only after 
the completion of the analysis, to ensure blinding of the person who 
analysed the data. Families and the caring physician were instructed 
not to discuss treatment with the study personnel. At completion of the 
study, the investigators were asked to guess the treatment allocation, in 
order to verify success of the investigator-blinded process.
2.7. Sample size calculations
A sample size of 40 children in each group [totalling 87 patients assum-
ing 10% dropout] was calculated to have 80% power to detect a dif-
ference in the mean PUCAI score of 10 points in the primary analysis, 
assuming standard deviation of 15 points, with an alpha of 0.05.
2.8. Statistics
Wilcoxon rank sum testing was used to compare the median PUCAI 
scores of the OD arm over the BD arm, and the other continuous 
data without normal distribution. Normally distributed variables 
were compared using Student’s t test. Categorical variables were 
compared using chi-square or Fisher’s exact tests, as appropriate. 
Missing data were imputed using the last observation carried forward 
[LOCF] method; analyses were performed using the modified ITT 
approach in which all patients taking at least one study medication 
were included in the analysis. No interim analyses were performed. 
Statistical analyses were performed using SPSS [IBM SPSS Statistics 
for Windows, Version 21.0. Armonk, NY] with p < 0.05 taken as the 
significance threshold.
All authors had access to the study data and reviewed and 
approved the final manuscript.
2.9. Ethics
The local research committee of each participating site approved the 
study. Informed consent was obtained from all participants and assent 
as appropriate. This investigator-initiated trial was partially funded by 
an educational grant from Ferring who also provided the study medi-
cation and monitoring service; however, Ferring were not involved 
in any part of the trial design, management, analyses, or manuscript 
preparation. No professional writing assistance has been provided.
3. Results
3.1. Patient disposition
A total of 86 children with UC were randomised in 13 centres affili-
ated with the authors of this manuscript; three were excluded from 
the ITT analysis, with a final total of 43 in the OD group and 40 in 
the BD group [Figure 1]. One child had severe disease according to 
the PUCAI and was mistakenly randomised due to an impression 
of general well-being; this child was not excluded. There were no 
statistical differences in any baseline parameters between the groups, 
including blood tests and disease activity [Table  2]. A  total of 24 
[29%] children dropped out due to disease aggravation, two [2%] 
were lost to follow-up, and one [1%] had an adverse event [5-ASA 
intolerance in the OD group] [Figure 1]. There was no difference 
in completion rates on the primary allocation between the OD (28 
[65%]) and BD (28 [70%]) groups; p > 0.2.
3.2. Primary and secondary outcomes
The study failed to show superiority of the OD group over the BD group 
in the PUCAI score at Week 6 (mean 23 ± 20 versus 19 ± 20; median 
15 [IQR 5–40] versus 10 [0–40]; absolute risk difference 4 ± 4.4 [95% 
86 randomized
43 allocated to Once daily 43 allocated to Twice daily
40 in the ITT analysis43 in the ITT analysis
28 (65%) completed 
     wk6 visit
15 (35%) did not 
complete wk6 visit:
13 (31%) aggravation of 
      the disease
1 (2%) adverse event
1 (2%) lost to follow-up
28 (70%) completed 
     wk6 visit
12 (30%) did not 
complete wk6 visit:
11 (28%) aggravation of 
     the disease
1 (2%) lost to follow-up
1 withdraw consent before receiving 
     study drug
1 Excluded for positive C. dif­cile
1 Excluded for having Crohn's disease
Figure 1. Participant flow diagram (Consolidated Standards of Reporting Trials [CONSORT diagram).
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confidence interval -4.6 to 12.6]; p = 0.48) [Figure 2]. No difference in 
the PUCAI score was found either in the secondary visits at Weeks 2, 
3, and 9 (mean 24 ± 17 versus 21 ± 16, 19 ± 17 versus 17 ± 17, and 
22 ± 21 versus 20 ± 20; median 20 [IQR 10–40] versus15 [5–25], 15 
[5–35] versus 15 [0–20], and 15 [0–35] versus 5 [0–20], respectively; 
all p > 0.2).
Under the secondary outcomes, the proportion of children in 
remission [PUCAI <  10] at Weeks 6 and 9 was similar between 
the OD and BD groups (13 [30%] versus 16 [40%]; p = 0.35, and 
15 [35%] versus 17 [43%]; p  = 0.48, respectively0 [Figure 5 and 
Figure 3]. The proportion of children in complete remission at Week 
6 was also similar (13 [31%] versus 13 [33%]; p = 0.88). The pro-
portion of children who responded [∆PUCAI ≥ 20] was similar at 
both Weeks 6 and 9 (25 [60%] versus 25 [63%]; p = 0.78, and 25 
[60%] versus 22 [55%]; p = 0.68, respectively) [Figure 5]. The pro-
portion of treatment success at Week 6 [PUCAI < 10 and a change of 
at least 10 points, or an improvement of at least 20 points] was 61% 
in the OD group versus 55% in the BD group [p = 0.61].
The mean IMPACT QOL [quality of life] questionnaire at 
Week 6 was similar between the OD [70  ±  12 points] and BD 
[75 ± 13] arms; p = 0.14 [Figure 4B]. Mean reported compliance 
with treatment was 94% in the OD versus 89% in the BD arms; 
p  =  0.17 [Figure 4C]. Similarly, MARS was similar between the 
groups [p = 0.29]. Median Week 6 CRP was similar between the 
OD and the BD groups (2.01  mg/l [IQR 0.83–7] versus 5  mg/l 
[1.23–6.1], respectively; p = 0.45) [Figure 4A]. There were no dif-
ferences in the median values of albumin, haemoglobin, or ESR at 
Week 6 [all p > 0.1].
Since this was an investigator-initiated study with limited fund-
ing, stool collection for faecal calprotectin [FC] was voluntary. 
Nonetheless there were 17 samples collected at the study comple-
tion (median 1590 g/g [IQR 653–2520]). The median nine FC values 
among the BD group tended to be lower than the eight values in 
the OD group but this did not reach statistical significance (653 g/g 
[IQR 398–2230] versus 2350 g/g [1426–3220]; p = 0.074).
In both groups combined, 29 of the 83 enrolled children [35%] were 
in clinical remission at Week 6. Most responders did so by Week 2 and 
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Figure  2. Paediatric Ulcerative Colitis Activity Index [PUCAI] scores in all 
study visits (last observation carried forward [LOCF] imputation).
Table 2. Baseline characteristics.
Total [n = 83] Once daily [n = 43] Twice daily [n = 40]
Males 43 [52%] 25 [58%] 18 [45%]
Age [years] 14 ± 2.7 14 ± 2.9 13.9 ± 2.6
Range 7–18 7–18 8–18
Disease duration [years] 0.2 [0.1–0.95] 0.2 [0.1–1] 0.2 [0.1–0.6]
New onset 36 [43%] 17 [40%] 19 [47%]
Disease extent
 Left sided 32 [39%] 13 [30%] 19 [48%]
 Extensive 8 [10%] 5 [12%] 3 [8%]
 Pancolitis 43 [52%] 25 [58%] 18 [45%]
Family history of IBD 16 [19%] 11 [26%] 5 [13%]
EIM 2 [2%] 2 [5%] 0 [0%]
Concomitant medications
 Thiopurines 4 [5%] 4 [9%] 0 [0%]
 Low dose 5-ASA 2 [2%] 1 [2%] 1 [2%]
 Probiotics 1 [1%] 1 [2%] 0 [0%]
 Rectal therapy 1 [1%] 1 [2%] 0 [0%]
 Biologics/steroids 0 [0%] 0 [0%] 0 [0%]
5-ASA dose after randomisation [g/day] 2.8 ± 0.5 2.8 ± 0.4 2.7 ± 0.5
Baseline PUCAI  40 [30–50] 42.5 [30–50]  40 [32.5–47.5]
 Mild 22 [27%] 12 [28%] 10 [25%]
 Moderate 60 [72%] 31 [72%] 29 [73%]
 Severe 1 [1%] 0 [0%] 1 [3%]
Baseline 100 mm VAS 41 ± 19 42 ± 17 41 ± 21
Baseline CRP [mg/l] 5 [1.6–12.2] 5 [1.8–14.4] 5 [1.5–10.5]
ESR 26 ± 19 25 ± 18 26 ± 19
Baseline albumin [g/dL] 4 ± 0.7 4 ± 0.5 4.1 ± 0.9
Baseline haemoglobin [g/dl] 12 ± 2.2 12.1 ± 2.1 11.8 ± 2.2
Medians [interquartile range] and means [± standard deviation] are presented as appropriate for the data distribution; none of the variables were statistically 
different between the groups.
IBD, inflammatory bowel disease; 5-ASA, 5-aminosalicylic acid; EIM, extraintestinal manifestations; PUCAI, paediatric UC activity index; VAS, visual ana-
logue scale;ESR, erythrocyte sedimentation rate.
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no further response was seen after Week 3. There was no association 
between remission rate and disease extent or duration [data not shown].
The sample sise of this trial was based on the hypothesis that 
OD would be superior to BD dosing. Although we failed to show 
superiority, a post-hoc analysis demonstrated that the observed dif-
ference meets the criteria for proving non-inferiority. The difference 
in the group’s mean PUCAI score at Week 6 was 3.3 points with a 
95% confidence interval [CI] of ± 4.4, indicating that the 95% CI of 
the mean difference is -1.1 to 7.7, crossing 0 from one hand but < 10 
points on the other hand. A difference of 10 points on the PUCAI is 
considered the minimal change score to be considered real beyond 
statistical error [ie, minimal detectable difference] and our difference 
is below that threshold.15 Nonetheless, this exploratory post-hoc 
analysis does not alter the conclusion of a failed superiority trial.
3.3. Safety
A total of 26 children had 35 adverse events; 17 [40%] in the OD 
group and nine [23%] in the BD group [p = 0.095], of which seven 
were severe (severe adverse events [[SAEs] four in the OD group and 
three in the BD group] [Table 3]. Withdrawals due to aggravation 
of disease or drug-related adverse events were similar, 14/43 [33%] 
in the OD and 11/40 [28%] in the BD, number needed to harm 
[NNH] = 20. None of the SAEs were thought to be related to the 
study drug [five aggravations of the colitis and need for intravenous 
steroids, one viral infection, and one peri-appendicular abscess].
Six children had AEs possibly related to the study drug: three in the 
OD group [one flu-like intolerance which required cessation of the drug, 
one abdominal pain, and one elevated transaminase] and three in the BD 
group [one headache, one chest pain, and one nausea with limb pain].
There were no differences between the OD and BD groups in 
Week-6 blood tests including creatinine, amylase, liver enzymes, bili-
rubin, γ-glutamyl transpeptidase [GGT], white blood cells, absolute 
neutrophil count and platelets, in any of the study visits. Urinalysis 
at both Weeks 3 and 6 did not reveal any alarming signals as com-
pared with baseline urinalysis [data not shown].
4. Discussion
In this first randomised controlled trial in children comparing once 
versus twice daily mesalazine in mild to moderate UC, we could 
not demonstrate superiority of the former for any of the outcomes 
including response, remission, safety, or adherence.
A high proportion of patients required additional therapy or 
a change in therapy before Week 6, suggesting overall low effec-
tiveness for mesalazine in mild to moderate paediatric UC. The 
intention-to-treat 35% remission rate at Week 6 is consistent with 
published data from other studies. Clinical remission in adults has 
been reported in only 28–46% of active patients.9 Comparisons 
between adult and paediatric results, however, are not straightfor-
ward. A  PUCAI-defined remission is more difficult to achieve as 
compared with a Mayo-defined remission, used in the aforemen-
tioned adult trials. A Mayo-defined remission may still allow some 
blood in the stool. We believe that complete remission should be 
measured, since it has been associated with favourable long-term 
outcome.27 Paediatric data to benchmark our results are scarce. 
A small trial with only 15 patients in the 5-ASA arm had a sim-
ilar PUCAI-defined remission rate of 35% at 8 weeks.5 Another 
paediatric trial found a PUCAI-defined remission rate of 40% in 
the standard-dose and 48% in the high-dose mesalazine groups, 
slightly higher than in our study.6 However, that trial included a 
higher proportion of children with mild disease [25% of children 
in our trial versus ~ 50% in the aforementioned study]. A North 
American paediatric registry found that only 31% of children with 
UC treated with 5-ASA at disease onset were in steroid-free remis-
sion and no treatment escalation at 1 year.28
According to the ESPGHAN-ECCO [European Society for Paediatric 
Gastroenterology Hepatology and Nutrition and European Crohn’s 
and Colitis Organisation] guidelines, 5-ASA is the first-line treatment 
in mild-moderate paediatric UC.24 However, paediatric gastroenterolo-
gists should be cognisant of the fact that this strategy will likely fail in 
most patients, requiring rapid treatment escalation, as recently recom-
mended.27 In our study, time to response was 2–3 weeks, such that lack 
of response by 3 weeks should trigger a change in treatment.
Theoretically, once daily dosing may be associated with better 
adherence to therapy, especially in children. Surprisingly, adherence and 
quality of life did not differ between the groups. This could be explained 
by the fact that our study enrolled active patients who are more likely 
to adhere to therapy. It is possible that adherence would be superior in 
the once-daily dosing group in a long term maintenance trial.
Our trial is the first to explore the utility of once-daily 5-ASA 
dosing in children, but it is not without limitations. We did not 
perform endoscopic evaluation of the bowel mucosa. However, 
according to the guidance of ECCO,25 endoscopic evaluation may 
be waived in paediatric trials of drugs which are not new cate-
gory, and 5-ASA most certainly falls into this class. Moreover, the 
PUCAI has proven in different studies to have a high concordance 
with sigmoidoscopic appearance in children, with an accuracy of 
80–90%.15,26,29 The OD arm had numerically more patients on 
immunomodulators and higher pancolitis rate [none reaching sta-
tistical significance]. We thus cannot exclude the possibility that the 
OD arm were still more severe, exerting a type II bias. Nonetheless, 
the two groups had similar disease activity as reflected by the 
PUCAI, PGA, and blood tests. Most of the patients in this study 
were not on concurrent topical therapy, which could have intro-
duced a bias towards milder disease even though the PUCAI 
reflected mild-to-moderate disease at inclusion. This is due to the 
study protocol which had an open-label extension arm in which 
patients unresponsive to oral therapy were treated with mesalazine 
enemas; the data are to be published as a separate study. This is 
unlikely to have influenced the outcomes, as over 70% of patients 
in both arms had moderate disease, and OD was still not superior 
to BD dosing.
Table 3. Adverse events.
Total  
[n = 83]
Once daily  
[n = 43]
Twice daily  
[n = 40]
Disease exacerbation 16 13 3
Headache 4 2 2
Abdominal pain 4 3 1
Fever 3 1 2
Nausea 2 0 2
Elevated liver enzymes, transient 2 2 0
5-ASA intolerancea 1 1 0
Macrohaematuriab 1 1 0
Chest pain 1 0 1
Peri-appendicular abscess 1 0 1
Death 0 0 0
Table presents the numbers of individual events and not number of chil-
dren; some may have had more than one event.
5-ASA, 5-aminosalicylic acid.
aFever, diarrhoea, abdominal pain, arthralgia.
bKnown to exist before the trial.
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Although our a priori hypothesis was that OD dosing would be 
superior to BD, mainly due to increased adherence and due to higher 
peak dose to the colon, a post hoc calculation showed that the dif-
ference between the groups falls also in the non-inferiority margin. 
This, along with similar numerical data across different outcomes 
and the consistent results of non-inferiority reported in several large 
adult trials, allows us to speculate that there are no differences 
between once daily or twice daily dosing in efficacy, safety, adher-
ence, or quality of life; however, a fully powered large non-inferiority 
trial is needed to prove this assumption.
Whereas once-daily dosing may be a valid option in children, our 
results are sufficient to enable a patient on twice-daily dosing who 
missed the morning dose to take the total daily dose later on. Our 
study adds another layer of evidence for developing guidelines for 
the treatment of UC in children and adolescents.
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